Wed, Jan 8, 2025 9:46 PM
Aditya Birla RE says no impact on Niyaara project after SC setback
A Flip by Shubhangi Gupta
Nomura upgrades Zydus Lifesciences' shares to "buy" from "hold" and raises its price target to ₹1,140, citing higher earnings estimates from the Sitagliptin 505b(2) drug. The brokerage sees an opportunity size of $100-150 million annually from the drug, despite competition in the US market. Nomura also notes benefits from a stronger US Dollar.
Open Flip
Global brokerage firm Nomura has downgraded its ratings on ACC, Shree Cement, and Nuvoco in its latest report stating that the Indian cement industry is experiencing significant headwinds over weak pricing power and sluggish demand growth. Nomura’s research note suggests that pan-India prices have remained flat in January 2025, with marginal improvements by Rs 60-70 in 3Q.
Open Flip
Indian markets witnessed a massive sell-off on Monday, ₹10 trillion is the amount of wealth that was lost on Monday this week as fear of the outbreak of a new virus i.e. Human Metapneumovirus (HMPV), gripped the market. There was a joke going rounds that while the first few patients were on their way to full recovery, the virus had sent the stock market to ICU.
Open Flip
